These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11174884)

  • 1. Cardiovascular basis for cholesterol therapy.
    Rackley CE
    Cardiol Rev; 2000; 8(2):124-31. PubMed ID: 11174884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive lipid therapy in the statin era.
    Farmer JA
    Prog Cardiovasc Dis; 1998; 41(2):71-94. PubMed ID: 9790411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of statins in the management of atherosclerosis.
    Vaughan CJ; Gotto AM; Basson CT
    J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of statins in acute coronary syndromes.
    Foody JM; Nissen SE
    Am J Cardiol; 2001 Aug; 88(4A):31F-5F. PubMed ID: 11520485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases].
    Windler E
    Internist (Berl); 2001 Jan; 42(1):92-110. PubMed ID: 11271625
    [No Abstract]   [Full Text] [Related]  

  • 13. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?
    Jacobson TA
    Ann Intern Med; 2000 Oct; 133(7):549-54. PubMed ID: 11015169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ; Bilek S; Rosenbaum S
    Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
    Ansell BJ; Watson KE; Fogelman AM
    JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.